TNF-related apoptosis-inducing ligand: Signalling of a 'smart' molecule

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 3, 2009, Pages 460-466

  Manzo, Fabio ^a,b   Nebbioso, Angela ^a   Miceli, Marco ^a   Conte, Mariarosaria ^a   De Bellis, Floriana ^a,b   Carafa, Vincenzo ^a   Franci, Gianluigi ^a   Tambaro, Francesco P ^a,c   Altucci, Lucia ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

Apoptosis; Cancer; Receptors; Signalling; TRAIL

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; BUTYRIC ACID; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; LEXATUMUMAB; MAPATUMUMAB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEASOME INHIBITOR; RAPAMYCIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; TRASDUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG HALF LIFE; GENE CONTROL; GENE STRUCTURE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 58149279571     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.12.012     Document Type: Short Survey

References (32)

1. Ashkenazi A., Pai R.C., and Fong S. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin Invest. 104 (1999) 155-162
2. Baetu T.M., Kwon H., Sharma S., Grandvaux N., and Hiscott J. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J. Immunol. 167 6 (2001) 3164-3173
3. Bodmer J., Meier P., Tschopp J., and Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem. 275 (2000) 20632-20637
4. Cretney E., Shanker A., Yagita H., Smyth M.J., and Sayers T.J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. 84 (2006) 87-98
5. Cretney E., Takeda K., and Yagita H. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168 (2002) 1356-1361
6. Earel J.K., Van Oosten R.L., and Griffith T.S. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 66 1 (2006) 499-507
7. Georgakis G.V., Li Y., and Rassidakis G.Z. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxygeldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin. Cancer Res. 12 (2006) 584-590
8. Gong B., and Almasan A. Genomic Organization and Transcriptional Regulation of Human Apo2/TRAIL Gene. Biochemical and Biophysical Research Communications. 278 3 (2000) 747-752
9. Huntington N.D., Vosshenrich C.A.J., and Di Santo J.P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7 (2007) 703-714
10. Hymowitz S.G., Christinger H.W., Fuh G., Ultsch M., O'Connell M., Kelley R.F., et al. Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4 (1999) 563-571
11. Inoue S., Mai A., Dyer M.J., and Cohen G.M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66 13 (2006) 6785-6792
12. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11 (2005) 71-76
13. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 9 (1999) 1451-1460
14. Kayagaki N., Yamaguchi N., Nakayama M., Takeda K., Akiba H., and Tsutsui H. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163 4 (1999) 1906-1913
15. Kelley S.K., Harris L.A., and Xie D. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31-38
16. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 6 (2000) 611-620
17. Lawrence D., Shahrokh Z., and Marsters S. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7 (2001) 383-385
18. Lub-de Hooge M.N., de Jong S., and Vermot-Desroches C. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. Shock 22 (2004) 186-188
19. Ma Y., Lakshmikanthan V., Lewis R.W., and Kumar M.V. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol. Cancer Ther. 5 (2006) 170-178
20. Mariani S.M., and Krammer P.H. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28 (1998) 973-982
21. Meurette O., Rebillard A., Huc L., Le Moigne G., Merino D., Micheau O., et al. TRAIL induces receptor-interacting protein 1-dependent and caspase-dependent necrosis-like cell death under acidic extracellular conditions. Cancer Res. 67 1 (2007) 218-226
22. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11 1 (2005) 77-84
23. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
24. Panner A., James C.D., Berger M.S., and Pieper R.O. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. 25 (2005) 8809-8823
25. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 22 (1996) 12687-12690
26. Sayers T.J., and Murphy W.J. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy cancer. Immunol. Immunother. 55 (2006) 76-84
27. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., et al. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187 8 (1998) 1205-1213
28. Schneider P., Thome M., Burns K., Bodmer J.L., Hofmann K., Kataoka T., et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7 6 (1997) 831-836
29. Van Oosten R.L., Earel J.K., and Griffith T.S. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 12 3 (2007) 561-571
30. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13 9 (2007) 1070-1077
31. Wang Q., Ji Y., Wang X., and Evers B.M. Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem. Biophys. Res. Commun. 276 (2000) 466-471
32. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 6 (1995) 673-682